Gräni R, Staub J J, Bechtel M, Müller J, Girard J, Stähelin H B, Burckhardt D
Schweiz Med Wochenschr. 1981 Jan 31;111(5):142-6.
The TRH test, using synthetic TRH (TSH-releasing hormone) is the most sensitive test for the assessment of thyroid function. It may show elevated basal TSH and/or an exaggerated TSH response to TRH, despite normal thyroid hormone levels (T4, FT4I, T3). This condition is termed "preclinical hypothyroidism" (pc hypo). Thyroid hormone levels, the clinical index of Billewicz and metabolic impact on target tissues were studied prospectively in 38 pc hypo women and compared with 20 controls matched for age, weight and sex and 9 patients with overt hypothyroidism. For metabolic evaluation at the tissue site two new metabolic tests were developed and standardized, the systolic time intervals (STI) and sex-hormone-binding globulin (SHBG), which were used in conjunction with the ankle reflex time (ART) and lipids (cholesterol and triglycerides). The thyroid hormones T4, FT4I and T3 in pc hypo (77.8 +/- 2.0 nmol/l; 71.8 +/- 2.3; 1.92 +/- 0.07 nmol/l respectively; mean +/- SEM) were within the normal range (by definition), but significantly lower in comparison with the normal controls (105.5 +/- 3.3 nmol/l; 97.8 +/- 3.1; 2.91 +/- 0.12 nmol/l respectively; p less than 0.001). The clinical index and metabolic parameters SHBG and ART showed significant hypothyroid changes. STI (measured as preejection period) and lipids were not yet significantly different from the controls despite a hypothyroid tendency in many single individuals. The etiology in 144 patients with pc hypo (out of 2969 TRH tests) was analysed and the following causes identified: a) treated hyperthyroidism (38 after radioiodine, 5 after partial thyroidectomy, 5 after antithyroid drugs, 5 after radioiodine and partial thyroidectomy); b) simple goiter (7 without and 21 after partial thyroidectomy); c) autoimmune thyroiditis (27); d) other causes such as subacute thyroiditis (10); Riedel's thyroiditis (2), dyshormogenesis (2), drugs (6), treated toxic adenomas (2); e) etiology unknown or not identified (14).
使用合成促甲状腺激素释放激素(TRH)的TRH试验是评估甲状腺功能最敏感的试验。尽管甲状腺激素水平(T4、游离甲状腺素指数[FT4I]、T3)正常,但该试验可能显示基础促甲状腺激素(TSH)升高和/或TSH对TRH的反应过度。这种情况被称为“亚临床甲状腺功能减退症”(亚临床甲减)。对38例亚临床甲减女性的甲状腺激素水平、Billewicz临床指数以及对靶组织的代谢影响进行了前瞻性研究,并与20名年龄、体重和性别匹配的对照组以及9例显性甲状腺功能减退症患者进行了比较。为了在组织部位进行代谢评估,开发并标准化了两项新的代谢试验,即收缩期时间间期(STI)和性激素结合球蛋白(SHBG),它们与踝反射时间(ART)和血脂(胆固醇和甘油三酯)一起使用。亚临床甲减患者的甲状腺激素T4、FT4I和T3(分别为77.8±2.0 nmol/L;71.8±2.3;1.92±0.07 nmol/L;平均值±标准误)在正常范围内(根据定义),但与正常对照组(分别为105.5±3.3 nmol/L;97.8±3.1;2.91±0.12 nmol/L;p<0.001)相比显著降低。临床指数以及代谢参数SHBG和ART显示出明显的甲状腺功能减退变化。尽管许多个体有甲状腺功能减退倾向,但STI(以射血前期测量)和血脂与对照组相比尚无显著差异。对2969例TRH试验中的144例亚临床甲减患者的病因进行了分析,确定了以下病因:a)治疗后的甲状腺功能亢进症(38例接受放射性碘治疗后,5例接受部分甲状腺切除术后,5例接受抗甲状腺药物治疗后,5例接受放射性碘和部分甲状腺切除术后);b)单纯性甲状腺肿(7例未手术,21例接受部分甲状腺切除术后);c)自身免疫性甲状腺炎(27例);d)其他病因,如亚急性甲状腺炎(10例)、Riedel甲状腺炎(2例)、激素合成障碍(2例)、药物(6例)、治疗后的毒性腺瘤(2例);e)病因不明或未确定(14例)。